Yiming Angko-B (01541): IMM0306 Phase III Clinical Trial Application for Follicular Lymphoma

According to the Zhitong Finance App, Yiming Angko-B (01541) issued an announcement. The Group has submitted an application for IMM0306 phase III clinical trial to the China National Drug Administration (CFDA) Drug Evaluation Center.

IMM0306, independently developed by the Group, is a bispecific molecule targeting differentiation cluster 47 (CD47) and differentiation cluster 20 (CD20). It is the world's first dual-targeted bispecific molecule of CD47 and CD20 to enter the clinical stage. IMM0306 blocks the “don't eat me” signal by inhibiting CD47-SIRPα interaction, enhances the interaction between FC-Fcriia and FC-FCriIIa to activate macrophages and NK cells, and prioritizes binding CD20 over CD47 to effectively eliminate malignant B cells while minimizing toxicity, thus improving the therapeutic effect.

As of the date of this announcement, the Group has IMM0306 global intellectual property rights and commercialization rights.